Stock Updates

Today’s Top Gainers in the Market Mylan N.V. (NASDAQ:MYL) from Healthcare

Today’s top gainers include the company Mylan N.V. (NASDAQ:MYL) which is in the industry Drugs – Generic, gaining -0.22% today. In the last week its performance is -5.71%, and -13.33% for the past quarter. Currently, Mylan N.V., MYL has a target price of 58.06, so today’s gain of -0.22% is a significant step towards its target price. The GAP today is therefore 1.09%.

Mylan N.V. (NASDAQ:MYL), has a market cap of 22614.31, and is based in USA. Insider ownership is at 0.70%, and institutional ownership is 64.50%.

At the current price of 40.31, it has a dividend yield of *TBA, and its target price is 58.06. This is with a profit margin of 8.10%, and total debt/equity of 1.31. Mylan N.V. (NASDAQ:MYL) has a P/E of 25.63, as well as a forward P/E of 6.92.

With a current EPS of 1.57, and a forecasted EPS growth for next year at 17.19%,Mylan N.V. (NASDAQ:MYL) has had a EPS growth for the past five years at 20.20%. For the next five years EPS growth is projected to be 14.16%.

Performance for the year is -17.26%. Since its IPO date on 12/18/1987, the total performance to date is -25.45%.

Volume today for Mylan N.V. (NASDAQ:MYL), is 6902600, while its average volume is 5590.32. Whilst the total gain today was -0.22%, it did have a day high of -20.02%.

Volatility for this week has been at 2.87%, and 3.10% for the month. The 52-week low for Mylan N.V., MYL has been 7.24%, while the 52-week-high has reached -27.38%.

Looking at its return of investments, which is 8.20%, and its return on assets is 3.40%. Mylan N.V. (NASDAQ:MYL) has an operating margin of 15.70%. With a sales growth of 8.00% quarter over quarter. Bearing in mind that Mylan N.V., MYL is in the sector Healthcare, its long-term debt/equity is 1.24, and has a current ratio of 3.2 and 2.6 for quick ratio.

So what is the value of Mylan N.V.? Well its PEG is 1.81, and the P/S is 2.28, along with a P/B of 1.97. Meanwhile it has a p/cash of 3.55.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment